Pharmaceutical companies in Saudi Arabia must soon comply with new regulations requiring pharmacoeconomic assessments. These assessments will help demonstrate the value of new drugs compared to existing treatments.
This change is part of an effort to ensure that new pharmaceutical products provide significant benefits over current options, potentially impacting market strategies and approval processes.